Organigram Pulls Sanity Group Into a Single Global Structure

TORONTO – Organigram Global Inc. did not wait out the calendar. Roughly four months after the April 2026 closing of its acquisition of Sanity Group GmbH, the Canadian Cannabis producer announced an accelerated integration of its German subsidiary under a unified global operating structure, backed by senior leadership changes and a restructured earnout agreement.

The original share purchase agreement required Sanity to operate on a standalone basis through a 12-month earnout period. Organigram has now amended that arrangement, replacing the performance-based structure with a fixed earnout set at 85% of the maximum value contemplated in the original deal. Under the revised terms, Sanity’s founders will receive €20 million in cash, with the remaining consideration (approx. €76 million) payable in Organigram shares. Both are due by May 2027.

The decision to convert the earnout early reflects Sanity’s performance since the acquisition closed. The Berlin company generated roughly C$40 million in Organigram’s most recent consolidated quarterly revenue, accounting for over 35% of the company’s total, and was accretive to adjusted EBITDA.

To lead the combined organization, Organigram has appointed Finn Age Hänsel [Sanity’s co-founder] as President, Rest of World & Chief Strategy Officer. Hänsel will oversee international market development, global corporate strategy, and the expansion of Organigram’s brands into new territories. Adrian Frenzel [formerly Sanity’s COO] has been named Global Chief Operating Officer, responsible for operational alignment and supply chain performance across both continents.

The integrated network will span Canada, Germany, Switzerland, Poland, Czechia, the United Kingdom and Australia. Organigram already exports bulk Cannabis shipments to Germany, Australia and the UK, and recently introduced 10 product SKUs into the Australian medical Cannabis market. On the European side, Sanity brings pharmacy distribution infrastructure, multilingual regulatory expertise, and a multi-brand portfolio.

The urgency behind full integration is tied to market. Germany’s medical Cannabis sector was valued at more than €2 billion in 2025, serving approximately 800,000 patients, and is projected to surpass €4 billion by 2028. Organigram’s acquisition of Sanity, originally structured at up to €250 million, is widely regarded as the largest Canadian entry into the German Cannabis market to date.

Overall, this restructuring carries a pointed signal for the broader Cannabis capital markets. Organigram is not treating Sanity as a strategic investment to be managed at arm’s length. By collapsing the standalone structure ahead of schedule, fixing the earnout early, and installing Sanity’s own founders at the global executive level, the company is placing a concentrated operational bet on European momentum.